| abstract |
A therapeutic nanoparticle comprising 2- (3 - ((7- (3- (ethyl (2-hydroxyethyl) amino) propoxy) quinazolin-4-yl) amino) -1H-pyrazol-5-yl) -N- (3 -fluorophenyl) acetamide (AZD1152 hqpa), which comprises 50 to 99.75 percent by weight of a poly (lactic acid) -poly (ethylene) glycol diblock copolymer, wherein the therapeutic nanoparticle comprises 10 to 30 percent in weight of poly (ethylene) glycol, and wherein the therapeutic nanoparticle comprises a substantially hydrophobic acid. |